Filtered By:
Specialty: Hematology
Condition: von Willebrand Disease

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 77 results found since Jan 2013.

Low ADAMTS ‐13 activity and the risk of coronary heart disease – a prospective cohort study: the Rotterdam Study
ConclusionsLow ADAMTS‐13 activity is associated with an increased risk of coronary heart disease in the elderly, independently of VWF and established cardiovascular risk factors.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - August 24, 2016 Category: Hematology Authors: M.A.H. Sonneveld, M. Kavousi, M.A. Ikram, A. Hofman, O.L. Rueda Ochoa, P.L. Turecek, O.H. Franco, F.W.G. Leebeek, M.P.M. de Maat Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Low ADAMTS-13 activity and the risk of coronary heart disease - a prospective cohort study: the Rotterdam Study.
CONCLUSIONS: Low ADAMTS-13 activity is associated with an increased risk of coronary heart disease in the elderly, independently of VWF and established cardiovascular risk factors. This article is protected by copyright. All rights reserved. PMID: 27559008 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - August 24, 2016 Category: Hematology Authors: Sonneveld MA, Kavousi M, Ikram MA, Hofman A, Rueda Ochoa OL, Turecek PL, Franco OH, Leebeek FW, de Maat MP Tags: J Thromb Haemost Source Type: research

Platelets and von Willebrand factor in atherogenesis
The role of platelet adhesion, activation, and aggregation in acute atherothrombotic events such as myocardial infarction and stroke is well established. There is increasing evidence that platelet-endothelial interactions also contribute to early atherosclerotic plaque initiation and growth. Through these interactions, platelet-derived factors can contribute to the proinflammatory and mitogenic status of resident mural cells. Among the many putative mechanisms for platelet-endothelial interactions, increased endothelial-associated von Willebrand factor, particularly in a multimerized form, which interacts with platelet gly...
Source: Blood - March 15, 2017 Category: Hematology Authors: Wu, M. D., Atkinson, T. M., Lindner, J. R. Tags: Hematopoiesis and Stem Cells, Thrombosis and Hemostasis, Vascular Biology, Blood Spotlight Source Type: research

Impact of Atrial Fibrillation on Platelet Gene Expression
ConclusionsPlatelets are capable to respond to the circulatory environment of NVAF by altering transcript and changing prothrombotic status. This shows platelet potential for molecular “reprogramming” possibly induced by flow disturbances of NVAF.This article is protected by copyright. All rights reserved.
Source: European Journal of Haematology - March 16, 2017 Category: Hematology Authors: Waldemar E. Wysokinski, Alfonso Tafur, Naser Ammash, Samuel J. Asirvatham, Yanhong Wu, Izabella Gosk ‐Bierska, Diane E. Grill, Joshua P. Slusser, Jozef Mruk, Robert D. McBane Tags: Original Article Source Type: research

Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation
AbstractRivaroxaban and Apixaban, increasingly used for stroke prevention in non-valvular atrial fibrillation (AF), might impact platelet reactivity directly or indirectly. By inhibition of Factor Xa (FXa) they preclude not only generation of relevant thrombin amounts but also block signalling of FXa via protease activated receptors. However, weather FXa-inhibition affects platelet haemostasis remains incompletely known. One hundred and twenty-eight patients with AF on chronic anticoagulation with either Rivaroxaban or Apixaban for at least 4 weeks were included in the study. In a time course group (25 on Rivaroxaban, 13 o...
Source: Journal of Thrombosis and Thrombolysis - April 1, 2017 Category: Hematology Source Type: research

Platelet receptors as therapeutic targets: Past, present and future.
Abstract Anti-platelet drugs reduce arterial thrombosis after plaque rupture and erosion, prevent stent thrombosis and are used to prevent and treat myocardial infarction and ischaemic stroke. Some of them may also be helpful in treating less frequent diseases such as thrombotic thrombocytopenic purpura. The present concise review aims to cover current and future developments of anti-platelet drugs interfering with the interaction of von Willebrand factor (VWF) with glycoprotein (GP) Ibα, and directed against GPVI, GPIIb/IIIa (integrin αIIbβ3), the thrombin receptor PAR-1, and the ADP receptor P2Y12. The high e...
Source: Thrombosis and Haemostasis - June 8, 2017 Category: Hematology Authors: Jamasbi J, Ayabe K, Goto S, Nieswandt B, Peter K, Siess W Tags: Thromb Haemost Source Type: research

Effect of Atrial Fibrillation Duration on Plasma von Willebrand Factor Level
ConclusionsVWF is steadily elevated throughout the course of dysrhythmia in NVAF patients treated with warfarin and in those with higher intensity of left atrium blood stasis.This article is protected by copyright. All rights reserved.
Source: European Journal of Haematology - September 27, 2017 Category: Hematology Authors: Waldemar E. Wysokinski, Kevin P. Cohoon, Ewa A. Konik, Rowlens M Melduni, Naser M. Ammash, Samuel J. Asirvatham, Robert D. McBane Tags: Original Article Source Type: research

Management of Hemostasis for Pediatric Patients on Ventricular-Assist Devices
Semin Thromb Hemost DOI: 10.1055/s-0037-1607982Ventricular-assist devices (VADs) have seen increased utilization in the pediatric population. Formerly, this therapeutic modality was limited to only the pulsatile VAD, EXCOR (Berlin Heart GmbH). However, the continuous flow VAD devices, HeartMate II (Abbott Inc.) and HeartWare (Medtronic Inc.), are now increasingly used in this population. Postoperatively, VAD patients are acutely anticoagulated using unfractionated heparin, often beginning 24 to 48 hours after VAD placement. Once the patient is stabilized and ready to transition to a lower acuity or outpatient setting, low-...
Source: Seminars in Thrombosis and Hemostasis - November 17, 2017 Category: Hematology Authors: Adachi, Iki Kostousov, Vadim Hensch, Lisa Chacon-Portillo, Martin A. Teruya, Jun Tags: Review Article Source Type: research

Hemostasis in the Very Young
Semin Thromb Hemost DOI: 10.1055/s-0038-1660852Hemostasis is a dynamic process that starts in utero. The coagulation system evolves with age, as evidenced by marked physiological differences in the concentration of the majority of hemostatic proteins in early life compared with adulthood. This concept, known as “developmental hemostasis,” has important biological and clinical implications. Overall, impaired platelet function, along with physiologically reduced levels of vitamin K–dependent and contact coagulation factors, may cause poorer clot firmness even in healthy neonates. However, increased activity of von Will...
Source: Seminars in Thrombosis and Hemostasis - June 18, 2018 Category: Hematology Authors: Kenet, Gili Barg, Assaf Arie Nowak-G öttl, Ulrike Tags: Review Article Source Type: research

Inflammation, von Willebrand factor, and ADAMTS13
Increasing evidence indicates that inflammation can cause thrombosis by a von Willebrand factor (VWF)-mediated mechanism that includes endothelial activation, secretion of VWF, assembly of hyperadhesive VWF strings and fibers, cleavage by ADAMTS13, and adhesion and deposition of VWF-platelet thrombi in the vasculature. This mechanism appears to contribute to thrombosis not only in small vessels, but also in large vessels. Inflammation and VWF contribute to atherogenesis and may contribute to arterial and venous thrombosis as well as stroke. Elucidation of the mechanism will hopefully identify new targets and suggest new ap...
Source: Blood - July 12, 2018 Category: Hematology Authors: Chen, J., Chung, D. W. Tags: Platelets and Thrombopoiesis, Thrombosis and Hemostasis, Vascular Biology, Review Articles, Review Series Source Type: research

Platelet Signaling in Primary Haemostasis and Arterial Thrombus Formation: Part 1.
Abstract Platelets react immediately in response to traumatic vascular injury by adhesion, activation, aggregation and subsequent haemostatic plug formation. While this reaction pattern is essential for haemostasis, platelet responses can also cause occlusive thrombi in diseased arteries, leading to myocardial infarction or stroke. Initially, flowing platelets are captured from the circulation to vascular lesions. This step is mediated by glycoprotein (GP) Ib-IX-V interacting with immobilized von Willebrand factor (VWF) on exposed subendothelial components. Tethered platelets can now bind to collagen through GPVI ...
Source: Hamostaseologie - October 23, 2018 Category: Hematology Authors: Scharf RE Tags: Hamostaseologie Source Type: research

Adult and pediatric mechanical circulation: a guide for the hematologist.
Authors: Kreuziger LB, Massicotte MP Abstract Mechanical circulatory support (MCS) is the overarching term that encompasses the temporary and durable devices used in patients with severe heart failure. MCS disturbs the hematologic and coagulation system, leading to platelet activation, activation of the contact pathway of coagulation, and acquired von Willebrand syndrome. Ischemic stroke and major hemorrhage occur in up to 30% of patients. Hematologists are an essential part of the MCS team because they understand the delicate balance between bleeding and clotting and alteration of hemostasis with antithrombotic th...
Source: Hematology ASH Education Program - December 7, 2018 Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

Von Willebrand Factor/ADAMTS-13 Interactions at Birth: Implications for Thrombosis in the Neonatal Period.
This article is protected by copyright. All rights reserved. PMID: 30593735 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 29, 2018 Category: Hematology Authors: Katneni UK, Ibla JC, Hunt R, Schiller T, Kimchi-Sarfaty C Tags: J Thromb Haemost Source Type: research

The Direct Thrombin Inhibitors Dabigatran and Lepirudin Inhibit GPIb α-Mediated Platelet Aggregation.
The Direct Thrombin Inhibitors Dabigatran and Lepirudin Inhibit GPIbα-Mediated Platelet Aggregation. Thromb Haemost. 2019 Apr 20;: Authors: Trabold K, Makhoul S, Gambaryan S, van Ryn J, Walter U, Jurk K Abstract The direct thrombin inhibitor (DTI) dabigatran is a non-vitamin K antagonist oral anticoagulant for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. In addition to its anti-thrombotic efficacy, dabigatran has been suggested to exert some pro-thrombotic effect due to fostering the ligation of thrombin to its high affinity platelet receptor glyco...
Source: Thrombosis and Haemostasis - April 19, 2019 Category: Hematology Authors: Trabold K, Makhoul S, Gambaryan S, van Ryn J, Walter U, Jurk K Tags: Thromb Haemost Source Type: research

P13. Abstract Title: Deep Mutational Scan of VWF to Define Mutations that Enhance or Impair Secretion
Von Willebrand Factor (VWF) is a multimeric glycoprotein that recruits platelets to sites of blood vessel injury and serves as a molecular chaperone for coagulation factor VIII (fVIII). Plasma VWF levels are a known risk factor for various thrombotic disorders including VTE, myocardial infarction, and stroke. GWAS studies have identified genetic variants in VWF that contribute to increased and decreased circulating VWF antigen levels. However, it is currently not known why some variants result in high VWF levels while others cause low VWF levels in circulation.
Source: Thrombosis Research - September 30, 2019 Category: Hematology Authors: T. Sparring, C. Kretz, K. Singh, H. Madarati Source Type: research